CABA-201 for Systemic Lupus Erythematosus (SLE)
Contact
Description
The purpose of this study is to find out what dose of CABA-201 ("study drug") can be safely administered to patients with Systemic Lupus Erythematosus and Lupus Nephritis. CABA-201 is a CAR T cell therapy drug, which uses your own T cells (immune cells), and modifies them in order to find and remove other immune cells (B cells) that cause this disease.
The cells will be collected through a process called leukapheresis, then modified in a lab. This modified version will be infused into the body.
Eligibility and criteria
What to expect
Participation will last for about 3 years. After that participants will be followed on the Long Term Follow Up portion of the study for up to 15 years following the CABA-201 infusion.
As a participant in the research you will:
Undergo leukapheresis to collect T-cells Receive lymphodepleting chemotherapy prior to infusion Receive study drug CABA-201 Undergo a kidney biopsy (if applicable) Stay in the hospital for at least 4 days after receiving the study drug Have research blood samples drawnRelated specialties
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.